Literature DB >> 406043

New agents for prostatic cancer activated specifically by prostatic acid phosphatase.

B D Paul, J A Serrano, A E Friedman, I J Sarlos, N J Sternberger, H L Wasserkrug, A M Seligman.   

Abstract

Potential cytotoxic compounds (spindle poisons) are being designed for the treatment of prostatic carcinoma, using the structural requirements of the substrates for prostatic acid phosphatase (PAP). Colchicine has been modified in ring C to give colchiceinamides of substituted ethanolamines and ethanolaminephosphates. Another new series of compounds modifying ring B of thiocolchicine have been prepared. Three O-phosphates of the thiocolchicine series have also been made. One has been examined for its specificity toward PAP. Some toxicity data of these compounds in mice have also been reported. Colchiceinamide-(L)-ephedrinephosphate has been examined in stumptail monkeys and some preliminary results are reported here.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 406043

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  2 in total

1.  D-Ephedrinephosphate, DEP: a new substrate with specificity for prostatic acid phosphatase (PAP).

Authors:  B D Paul; J A Serrano; H L Wasserkrug; A A Serrano; A M Seligman
Journal:  Histochemistry       Date:  1978-06-09

Review 2.  Microbial cytosine deaminase is a programmable anticancer prodrug mediating enzyme: antibody, and gene directed enzyme prodrug therapy.

Authors:  Ashraf S A El-Sayed; Nabil Z Mohamed; Marwa A Yassin; Mahmoud M Amer; Reyad El-Sharkawy; Nesma El-Sayed; Mostafa G Ali
Journal:  Heliyon       Date:  2022-09-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.